Patterns of use and harm reduction practices of ecstasy users in Australia

Drug and Alcohol Dependence

Volumn 82, Issue 2, 2006, Pages 168-176

  Allott, Kelly ^a   Redman, Jennifer ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Adverse effects; Ecstasy; Harm reduction; MDMA; Survey research

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 5 HYDROXYTRYPTOPHAN; DRINKING WATER; ILLICIT DRUG; MAGNESIUM; MULTIVITAMIN;

ADULT; ARTICLE; AUSTRALIA; CONTROLLED STUDY; DRUG USE; FEMALE; FRUIT JUICE; HARM REDUCTION; HUMAN; LIFESPAN; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PRIORITY JOURNAL; QUESTIONNAIRE; SNOWBALL SAMPLE; VITAMIN SUPPLEMENTATION;

ADULT; AUSTRALIA; HUMANS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PATIENT ACCEPTANCE OF HEALTH CARE; QUESTIONNAIRES; RISK REDUCTION BEHAVIOR; SUBSTANCE-RELATED DISORDERS;

EID: 33645220937     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2005.09.009     Document Type: Article

References (49)

1. N. Aguirre, M. Barrionuevo, M.J. Ramirez, J. Del Rio, and B. Lasheras Alpha-lipoic acid prevents 3,4-methylenedioxy-methamphetamine (MDMA)-induced neurotoxicity Neuroreport 10 1999 3675 3680
2. G. Akram, and M. Galt A profile of harm-reduction practices and co-use of illicit and licit drugs amongst users of dance drugs Drugs: Educ., Prev. Policy 6 1999 215 225
3. Australian Institute of Health and Welfare (AIHW), 2002. 2001 National Drug Strategy Household Survey: First Results. Drug Statistics Series No. 9 (AIHW cat. no PHE 35), pp. 1-20.
4. M.J. Baggott Preventing problems in ecstasy users: reduce use to reduce harm J. Psychoactive Drugs 34 2002 145 162
5. P. Biernacki, and D. Waldorf Snowball sampling: problems and techniques of chain referral sampling Sociol. Methods Res. 10 1981 141 163
6. B.P. Boot, I.S. McGregor, and W. Hall MDMA (ecstasy) neurotoxicity: assessing and communicating the risks Lancet 355 2000 1818 1821
7. A. Boys, S. Lenton, and K. Norcoss Polydrug use at raves by a Western Australian sample Drug Alcohol Rev. 16 1997 227 234
8. R. Buchert, R. Thomasius, B. Nebeling, K. Petersen, J. Obrocki, L. Jenicke, F. Wilke, L. Wartberg, P. Zapletalova, and M. Clausen Long-term effects of "ecstasy" use on serotonin transporters of the brain investigated by PET J. Nucl. Med. 44 2003 375 384
9. J. Cole Ecstasy tablet testing: a case of guilty until proven innocent? Addiction 97 2002 231 232
10. L. Degenhardt, B. Barker, and L. Topp Patterns of ecstasy use in Australia: findings from a national household survey Addiction 99 2003 187 195
11. A. Gamma, L. Jerome, M.E. Liechti, and H.R. Sumnall Is ecstasy perceived to be safe? A critical survey Drug Alcohol Depend. 77 2005 185 193
12. P.K. Gillman The serotonin syndrome and its treatment J. Psychopharmacol. 13 1999 100 109
13. A. Green, A.J. Cross, and G.M. Goodwin Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") Psychopharmacology 119 1995 247 260
14. A.R. Green, A.O. Mechan, J.M. Elliott, E. O'Shea, and M.I. Colado The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") Pharmacol. Rev. 55 2003 463 508
15. G.A. Gudelsky Effect of ascorbate and cysteine on the 3,4-methylenedioxymethamphetamine-induced depletion of brain serotonin J. Neural. Trans. 103 1996 1397 1404
16. G.A. Gudelsky, and B.K. Yamamoto Neuropharmacology and neurotoxicity of 3,4-methylenedioxymethamphetamine Methods Mol. Med. 79 2003 55 73
17. D. Hansen, B. Maycock, and T. Lower 'Weddings, parties, anything...', a qualitative analysis of ecstasy use in Perth, Western Australia Int. J. Drug Policy 12 2001 181 199
18. K.M. Hegadoren, G.B. Baker, and M. Bourin 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans Neurosci. Biobehav. Rev. 23 1999 539 553
19. R.A. Hurley, L. Reneman, and K.H. Taber Ecstasy in the brain: a model for neuroimaging J. Neuropsychiatry Clin. Neurosci. 14 2002 125 129
20. A. Jones, and G. Volans Management of self poisoning BMJ 319 1999 1414 1417
21. Khadem, N., 18 April 2004. Legalised testing of party drugs urged to save lives. The Sunday Age, Melbourne, Australia, p. 6.
22. J.E. Malberg, K.E. Sabol, and L. Seiden Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat J. Pharmacol. Exp. Ther. 278 1996 258 267
23. U.D. McCann, and G.A. Ricaurte Reinforcing subjective effects of (±) 3,4-methylenedioxymethamphetamine ("ecstasy") may be separable from its neurotoxic actions: clinical evidence J. Clin. Psychopharmacol. 13 1993 214 217
24. U.D. McCann, Z. Szabo, U. Scheffel, R.F. Dannals, and G. Ricaurte Positron emission tomographic evidence of toxic effect of MDMA ("ecstasy") on brain serotonin neurons in human beings Lancet 352 1998 1433 1437
25. F. Measham, J. Aldrigde, and H. Parker Dancing on Drugs: Risks, Health and Hedonism in the British Club Scene 2001 Free Association Books London
26. Moncrief, M., Stevenson, A., 21st August 2004. Push to test nightclub ecstasy. The Age, Melbourne, Australia, p. 5.
27. A.G. Montoya, R. Sorrentino, S.E. Lukas, and B.H. Price Long-term neuropsychiatric consequences of "ecstasy" (MDMA): a review Harv. Rev. Psychiatry 10 2002 212 220
28. R.A. Murray, P.L. Doering, L.A. Boothby, M.L. Merves, R.R. McCusker, C.W. Chronister, and B.A. Goldberger Putting an ecstasy test kit to the test: harm reduction or harm induction? Pharmacotherapy 23 2003 1238 1244
29. National Drug and Alcohol Research Centre (NDARC), 2004. Ecstasy study identifies potentially lethal combination. Retrieved 15 November 2004, from http://ndarc.med.unsw.edu.au/ndarc.nsf/website/news.pressreleases.
30. J.R. Oesterheld, S.C. Armstrong, and K.L. Cozza Ecstasy: pharmacodynamic and pharmacokinetic interactions Psychosomatics 45 2004 84 87
31. A. Parrott Human psychopharmacology of ecstasy (MDMA): a review of 15 years of empirical research Hum. Psychopharmacol. 16 2001 557 577
32. L. Reneman, J. Booij, K. de Bruin, J.R. Reitsma, F.A. de Wolff, W. Gunning, G.J. den Heeten, and W. van den Brink Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons Lancet 358 2001 1864 1869
33. G.A. Ricaurte, J. Yuan, and U.D. McCann (±)3,4- Methylenedioxymethamphetamine ('ecstasy')-induced serotonin neurotoxicity: studies in animals Neuropsychobiology 42 2002 5 10
34. F. Schifano, L. Di Furia, G. Forza, N. Minicuci, and R. Bricolo MDMA ('ecstasy') consumption in the context of polydrug abuse: a report on 150 patients Drug Alcohol Depend. 52 1998 85 90
35. F. Schifano, A. Oyefeso, J. Corkery, K. Cobain, R. Jambert-Gray, G. Martinotti, and A. Ghodse Death rates from ecstasy (MDMA, MDA) and polydrug use in England and Wales 1996-2002 Hum. Psychopharmacol. 18 2003 519 524
36. A.B. Scholey, A.C. Parrott, T. Buchanan, T.M. Heffernan, J. Ling, and J. Rodgers Increased intensity of ecstasy and polydrug usage in the more experienced recreational ecstasy/MDMA users: a WWW study Addict. Behav. 29 2004 743 752
37. M. Shankaran, B.K. Yamamoto, and G.A. Gudelsky Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3,4-methylenedioxymethamphetamine Eur. J. Pharmacol. 385 1999 103 110
38. M. Shankaran, B.K. Yamamoto, and G.A. Gudelsky Ascorbic acid prevents 3,4-methylenedioxymethamphetamine (ecstasy)-induced hydroxyl radical formation and the behavioural and neurochemical consequences of the depletion of brain 5-HT Synapse 40 2001 55 64
39. K. Sherlock, and M. Conner Patterns of ecstasy use amongst club-goers on the UK 'dance scene' Int. J. Drug Policy 10 1999 117 129
40. D. Shewan, P.H. Dalgarno, and R. Reith Perceived risk and risk reduction among ecstasy users: the role of drug, set, and setting Int. J. Drug Policy 10 2000 431 453
41. N. Solowij, W. Hall, and N. Lee Recreational MDMA use in Sydney: a profile of 'ecstasy' users and their experiences with the drug Br. J. Addict. 87 1992 1161 1172
42. J.E. Sprague, X. Huang, A. Kanthasamy, and D.E. Nichols Attenuation of 3,4-methylenedioxymethamphetamine (MDMA) induced neurotoxicity with the serotonin precursors tryptophan and 5-hydroxytryptophan Life Sci. 55 1994 1193 1198
43. T. Tong, and E.W. Boyer Club drugs, smart drugs, raves, and circuit parties: an overview of the club scene Pediatr. Emerg. Care 18 2002 216 218
44. L. Topp, J. Hando, P. Dillon, A. Roche, and N. Solowij Ecstasy use in Australia: patterns of use and associated harm Drug Alcohol Depend. 55 1999 105 115
45. G.M. van de Wijngaart, R. Braam, D. de Bruin, M. Fris, N.J.M. Maalste, and H.T. Verbraeck Ecstasy use at large-scale dance events in The Netherlands J. Drug Issues 29 1999 679 702
46. E. Weir Raves: a review of the culture, the drugs and the prevention of harm Can. Med. Assoc. J. 162 2000 1843 1848
47. S. Williamson, M. Gossop, B. Powis, P. Griffiths, J. Fountain, and J. Strang Adverse effects of stimulant drugs in a community sample of drug users Drug Alcohol Depend. 44 1997 87 94
48. A.R. Winstock, P. Griffiths, and D. Stewart Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK Drug Alcohol Depend. 64 2001 9 17
49. A.R. Winstock, K. Wolff, and J. Ramsey Ecstasy pill testing: harm minimization gone too far? Addiction 96 2001 1139 1148